

APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

Purchase of own shares - 4th Interim notification

Monheim am Rhein, 07 April 2022. In the period from 04 April 2022 up to and including 06 April 2022, a total of 30,003 shares were purchased under the Share Buyback Program 2022. The launch and the details of the Share Buyback Program 2022 were published by way of an announcement dated 15 March 2022 pursuant to Article 5 paragraph 1 of Regulation (EU) No. 596/2014 and Article 2 paragraph 1 of the Delegated Regulation (EU) No. 2016/1052.

The total number of shares purchased in the period from 04 April 2022 up to and including 06 April 2022 per day, exchange, average price and volume in euros are as follows:

Date	Total number of shares purchased (number)	Average price (Euro)	Exchange	Volume (EUR) ¹
04/04/2022	165	12.2937	Xetra	2,028.30
05/04/2022	9,497	11.7755	Xetra	111,832.25
06/04/2022	1,309	11.3021	Xetra	14,794.40

1) Excluding acquisition costs

The total number of shares purchased to date as part of the Share Buyback Program 2022 up to and including 06 April 2022 amounts to 70,000 shares.

The share buyback was carried out by Hauck Aufhäuser Lampe Privatbank AG.

Further details on the Share Buyback Program 2022 and the above transactions are published under the Corporate Governance section of the Company's Investor Relations website in accordance with Article 5 of Regulation (EU) No. 596/2014 and



pursuant to Delegated Regulation (EU) No. 2016/1052 (<https://ir.apontis-pharma.de/websites/apontispharma/English/4000/corporate-governance.html>).